Trial NCT02703272

View at ClinicalTrials.gov 
Org. Study IDs: CR108134
Secondary IDs: 2016-000259-28 54179060LYM3003

Last trial update was posted on 2022-12-02

MeSH Interventions

Carboplatin Dexamethasone Etoposide Ibrutinib Idarubicin Ifosfamide Rituximab Vincristine

MeSH Conditions

Lymphoma Lymphoma, B-Cell Lymphoma, Non-Hodgkin

Other Conditions


Stopping Reasons

IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID